| Literature DB >> 29540749 |
Wenlong Zhou1, Yan Yang1, Liang Tang2, Kai Cheng3, Changkun Li4, Huimin Wang2, Minzhi Liu2, Wei Wang5.
Abstract
Acrolein (Acr) was used as a selection agent to improve the glutathione (GSH) overproduction of the prototrophic strain W303-1b/FGPPT. After two rounds of adaptive laboratory evolution (ALE), an unexpected result was obtained wherein identical GSH production was observed in the selected isolates. Then, a threshold selection mechanism of Acr-stressed adaption was clarified based on the formation of an Acr-GSH adduct, and a diffusion coefficient (0.36 ± 0.02 μmol·min-1·OD600-1) was calculated. Metabolomic analysis was carried out to reveal the molecular bases that triggered GSH overproduction. The results indicated that all three precursors (glutamic acid (Glu), glycine (Gly) and cysteine (Cys)) needed for GSH synthesis were at a relativity higher concentration in the evolved strain and that the accumulation of homocysteine (Hcy) and cystathionine might promote Cys synthesis and then improve GSH production. In addition to GSH and Cys, it was observed that other non-protein thiols and molecules related to ATP generation were at obviously different levels. To divert the accumulated thiols to GSH biosynthesis, combinatorial strategies, including deletion of cystathionine β-lyase (STR3), overexpression of cystathionine γ-lyase (CYS3) and cystathionine β-synthase (CYS4), and reduction of the unfolded protein response (UPR) through up-regulation of protein disulphide isomerase (PDI), were also investigated.Entities:
Mesh:
Substances:
Year: 2018 PMID: 29540749 PMCID: PMC5852114 DOI: 10.1038/s41598-018-22836-2
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Progress of the selection of GSH-overproducing strains in shaken flasks. (A) Glutathione was measured at the indicated generation times after cultivation for 48 h in WMVIII media. The selection started from strains W303-1b/FGPPT and W303-1b/FGPPTm. The population was grown in WMVIII medium supplemented initially with 0.2 mM Acr and exposed to sequential serial passages by increasing the Acr dose. (B) The second round of the ALE experiments started from the isolate W303-1b/FGPPT-8 after the first-round ALE experiment. Glutathione was measured as described above. (C) GSH accumulation of the parental strain W303-1b/FGPPT and the evolved strain W303-1b/FGPPT-8–12. (D) Growth behaviour of the parental strain and the evolved strain. ‘m’ refers to yeast strains treated with 50 μg/mL MNNG before the ALE experiment was conducted. ‘A’ and ‘AM’ refer to the ALE assay using Acr as a selection agent without or with MNNG. The values are presented as the means, and the error bars show the SD (n = 3). When not shown, error bars lie within the symbols.
Figure 2The accumulation of Acr-GSH in the evolved strain W303-1b/FGPPT-8–12 in the first 60 min of treatment with 1.2 mM Acr. The equation for the linear region was y = 0.18 (±0.01) x + 0.04 (±0.30) with a correlation coefficient (R) of 0.961.
Figure 3Heat map of the metabolites from the evolved strain W303-1b/FGPPT-8–12 obtained from the ALE experiments and the parental strain W303-1b/FGPPT. Rows represent specific intracellular metabolites. Columns represent different cell growth intervals (12, 24, 36, 48 and 60 h). Fold change was used to evaluate the relative concentration of metabolites of W303-1b/FGPPT-8–12 and W303-1b/FGPPT.
Figure 4The effects of modulation of the Cys synthesis pathway and overexpression of PDI on the GSH accumulation and DCWs of the evolved strain W303-1b/FGPPT-8–12 and the engineered strain W303-1b/FGPPT. (A) GSH production (mg/L). (B) DCW (g/L). (C) GSH content (%). The values are presented as the means, and the error bars show the SD (n = 3).
Figure 5GSH production and DCW of combinatorial strains with the modulation of both the Cys biosynthetic pathway and PDI. (A) GSH production of combinatorial strains based on the evolved strain W303-1b/FGPPT-8–12 and the engineered strain W303-1b/FGPPT. (B) DCW (g/L). (C) GSH content (%). The values are presented as the means, and the error bars show the SD (n = 3). ‘Control’ represents W303-1b/FGPPT-8–12/ΔSTR3 and W303-1b/FGPPT/ΔSTR3, respectively.
Strains and plasmids used in this study.
| Strains and plasmids | Relevant properties | Source or references |
|---|---|---|
|
| ||
|
| Our lab | |
|
| Our lab | |
| W303-1b/FGP | The parental strain with the three-pathway engineered strain derived from W303-1b | Tang |
| W303-1b/FGPPT | Prototrophic strain, a derivative of W303-1b/FGP via the reversion | This study |
| W303-1b/FGPPT-8 | GSH overproduction strain obtained from the first round of ALE experiments | This study |
| W303-1b/FGPPT-8–12 | GSH overproduction strain obtained from the second round of ALE experiments | This study |
| W303-1b/FGPPT/CYS3 | W303-1b/FGPPT derivative with the integration of pδGAPh-CYS3 | This study |
| W303-1b/FGPPT/CYS4 | W303-1b/FGPPT derivative with the integration of pδGAPg-CYS4 | This study |
| W303-1b/FGPPT/CYS3/CYS4 | W303-1b/FGPPT derivative with the integration of pδGAPh-CYS3 and pδGAPg-CYS4 | This study |
| W303-1b/FGPPT/ΔSTR3 | W303-1b/FGPPT derivative with the disruption of | This study |
| W303-1b/FGPPT/PDI | W303-1b/FGPPT derivative with the integration pδPGKb-PDI | This study |
| W303-1b/FGPPT/ΔSTR3/CYS3/CYS4 | W303-1b/FGPPT/ΔSTR3 derivative with the integration of pδGAPh-CYS3 and pδGAPg-CYS4 | This study |
| W303-1b/FGPPT/ΔSTR3/CYS3/CYS4/PDI | W303-1b/FGPPT/ΔSTR3/CYS3/CYS4 derivative with the integration of pδPGKb-PDI | This study |
| W303-1b/FGPPT-8–12/CYS3 | W303-1b/FGPPT-8–12 derivative with the integration of pδGAPh-CYS3 | This study |
| W303-1b/FGPPT-8–12/CYS4 | W303-1b/FGPPT-8–12 derivative with the integration of pδGAPg-CYS4 | This study |
| W303-1b/FGPPT-8–12/CYS3/CYS4 | W303-1b/FGPPT-8–12 derivative with the integration of pδGAPh-CYS3 and pδGAPg-CYS4 | This study |
| W303-1b/FGPPT-8–12/ΔSTR3 | W303-1b/FGPPT-8–12 derivative with the disruption of | This study |
| W303-1b/FGPPT-8–12/PDI | W303-1b/FGPPT-8–12 derivative with the integration of pδPGKb-PDI | This study |
| W303-1b/FGPPT-8–12/ΔSTR3/CYS3/CYS4 | W303-1b/FGPPT-8–12/ΔSTR3 derivative with the integration of pδGAPh-CYS3 and pδGAPg-CYS4 | This study |
| W303-1b/FGPPT-8–12/ΔSTR3/CYS3/CYS4/PDI Plasmids | W303-1b/FGPPT-8–12/ΔSTR3/CYS3/CYS4 derivative with the integration of pδPGKb-PDI | This study |
| pδGAPh | pBluescript II KS(+) derivative with homologous δ region, Pgap, Tpgk1, HygBr | Our lab |
| pδGAPg | pBluescript II KS(+) derivative with homologous δ region, Pgap, Tpgk1, G418r | Our lab |
| pδPGKb | pBluescript II KS(+) derivative with homologous δ region, Ppgk1, Tpgk1, Blar | Our lab |
| pδGAPz | pBluescript II KS(+) derivative with homologous δ region, Pgap, Tpgk1, Zeor | Our lab |
| pδGAPh-CYS3 | pδGAPh derivative with | This study |
| pδGAPg-CYS4 | pδPGKb derivative with | This study |
| pδPGKb-PDI | pδGAPz derivative with | This study |